These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 15265851)

  • 21. Viral hepatitis and hepatocellular carcinoma.
    Marrero CR; Marrero JA
    Arch Med Res; 2007 Aug; 38(6):612-20. PubMed ID: 17613352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of vitamin K2 in preventing the recurrence of hepatocellular carcinoma after curative treatment: a meta-analysis of randomized controlled trials.
    Riaz IB; Riaz H; Riaz T; Rahman S; Amir M; Badshah MB; Kazi AN
    BMC Gastroenterol; 2012 Nov; 12():170. PubMed ID: 23191943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group.
    Lancet; 1998 May; 351(9115):1535-9. PubMed ID: 10326535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of hepatocellular carcinoma in chronic viral hepatitis patients with cirrhosis by carotenoid mixture.
    Nishino H
    Recent Results Cancer Res; 2007; 174():67-71. PubMed ID: 17302186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vitamins K2, K3 and K5 exert in vivo antitumor effects on hepatocellular carcinoma by regulating the expression of G1 phase-related cell cycle molecules.
    Kuriyama S; Hitomi M; Yoshiji H; Nonomura T; Tsujimoto T; Mitoro A; Akahane T; Ogawa M; Nakai S; Deguchi A; Masaki T; Uchida N
    Int J Oncol; 2005 Aug; 27(2):505-11. PubMed ID: 16010434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathologic features and risk factors for hepatocellular carcinoma: results from a single center in southern Turkey.
    Ozer B; Serin E; Yilmaz U; Gümürdülü Y; Saygili OB; Kayaselçuk F; Boyacioğlu S
    Turk J Gastroenterol; 2003 Jun; 14(2):85-90. PubMed ID: 14614632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High incidence of hepatocellular carcinoma in ESRD patients: caused by high hepatitis rate or 'uremia'? a population-based study.
    Hwang JC; Weng SF; Weng RH
    Jpn J Clin Oncol; 2012 Sep; 42(9):780-6. PubMed ID: 22782961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease.
    Eun JR; Lee HJ; Kim TN; Lee KS
    J Hepatol; 2010 Jul; 53(1):118-25. PubMed ID: 20471129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phytochemicals in hepatocellular cancer prevention.
    Nishino H
    Nutr Cancer; 2009; 61(6):789-91. PubMed ID: 20155617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis.
    Ioannou GN; Splan MF; Weiss NS; McDonald GB; Beretta L; Lee SP
    Clin Gastroenterol Hepatol; 2007 Aug; 5(8):938-45, 945.e1-4. PubMed ID: 17509946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis.
    Nishiguchi S; Shiomi S; Nakatani S; Takeda T; Fukuda K; Tamori A; Habu D; Tanaka T
    Lancet; 2001 Jan; 357(9251):196-7. PubMed ID: 11213099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study.
    Mizuta T; Ozaki I; Eguchi Y; Yasutake T; Kawazoe S; Fujimoto K; Yamamoto K
    Cancer; 2006 Feb; 106(4):867-72. PubMed ID: 16400650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of viral load and genotype in the progression of Hepatitis B-associated liver cirrhosis to hepatocellular carcinoma.
    Mahmood S; Niiyama G; Kamei A; Izumi A; Nakata K; Ikeda H; Suehiro M; Kawanaka M; Togawa K; Yamada G
    Liver Int; 2005 Apr; 25(2):220-5. PubMed ID: 15780042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection.
    Hosaka T; Suzuki F; Kobayashi M; Seko Y; Kawamura Y; Sezaki H; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    Hepatology; 2013 Jul; 58(1):98-107. PubMed ID: 23213040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and pathological factors associated with the development of hepatocellular carcinoma in patients with hepatitis virus-related cirrhosis: a long-term follow-up study.
    Rodríguez-Díaz JL; Rosas-Camargo V; Vega-Vega O; Morales-Espinosa D; Mendez-Reguera A; Martínez-Tlahuel JL; Gamboa-Domínguez A; Arrieta O
    Clin Oncol (R Coll Radiol); 2007 Apr; 19(3):197-203. PubMed ID: 17359907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.
    Ascha MS; Hanouneh IA; Lopez R; Tamimi TA; Feldstein AF; Zein NN
    Hepatology; 2010 Jun; 51(6):1972-8. PubMed ID: 20209604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma.
    Chen CF; Lee WC; Yang HI; Chang HC; Jen CL; Iloeje UH; Su J; Hsiao CK; Wang LY; You SL; Lu SN; Chen CJ;
    Gastroenterology; 2011 Oct; 141(4):1240-8, 1248.e1-2. PubMed ID: 21703214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Prevention of hepatocellular carcinogenesis by interferon].
    Ikeda K
    Nihon Rinsho; 2001 Oct; 59 Suppl 6():755-63. PubMed ID: 11762051
    [No Abstract]   [Full Text] [Related]  

  • 39. The risk of liver and bile duct cancer in patients with chronic viral hepatitis, alcoholism, or cirrhosis.
    Kuper H; Ye W; Broomé U; Romelsjö A; Mucci LA; Ekbom A; Adami HO; Trichopoulos D; Nyrén O
    Hepatology; 2001 Oct; 34(4 Pt 1):714-8. PubMed ID: 11584367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus.
    Adachi S; Shibuya A; Miura Y; Takeuchi A; Nakazawa T; Saigenji K
    Scand J Gastroenterol; 2008; 43(7):849-56. PubMed ID: 18584524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.